Literature DB >> 31852795

Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition.

Na Kong1,2, Wei Tao3, Xiang Ling1, Junqing Wang1, Yuling Xiao1, Sanjun Shi1, Xiaoyuan Ji1,4, Aram Shajii1, Silvia Tian Gan1,5, Na Yoon Kim1, Dan G Duda6, Tian Xie7, Omid C Farokhzad3,8, Jinjun Shi3.   

Abstract

Loss of function in tumor suppressor genes is commonly associated with the onset/progression of cancer and treatment resistance. The p53 tumor suppressor gene, a master regulator of diverse cellular pathways, is frequently altered in various cancers, for example, in ~36% of hepatocellular carcinomas (HCCs) and ~68% of non-small cell lung cancers (NSCLCs). Current methods for restoration of p53 expression, including small molecules and DNA therapies, have yielded progressive success, but each has formidable drawbacks. Here, a redox-responsive nanoparticle (NP) platform is engineered for effective delivery of p53-encoding synthetic messenger RNA (mRNA). We demonstrate that the synthetic p53-mRNA NPs markedly delay the growth of p53-null HCC and NSCLC cells by inducing cell cycle arrest and apoptosis. We also reveal that p53 restoration markedly improves the sensitivity of these tumor cells to everolimus, a mammalian target of rapamycin (mTOR) inhibitor that failed to show clinical benefits in advanced HCC and NSCLC. Moreover, cotargeting of tumor-suppressing p53 and tumorigenic mTOR signaling pathways results in marked antitumor effects in vitro and in multiple animal models of HCC and NSCLC. Our findings indicate that restoration of tumor suppressors by the synthetic mRNA NP delivery strategy could be combined together with other therapies for potent combinatorial cancer treatment.
Copyright © 2019 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31852795      PMCID: PMC7024563          DOI: 10.1126/scitranslmed.aaw1565

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  93 in total

Review 1.  mTOR signaling in growth control and disease.

Authors:  Mathieu Laplante; David M Sabatini
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582

2.  AMP-activated protein kinase and the regulation of autophagic proteolysis.

Authors:  Daniel Meley; Chantal Bauvy; Judith H P M Houben-Weerts; Peter F Dubbelhuis; Mariette T J Helmond; Patrice Codogno; Alfred J Meijer
Journal:  J Biol Chem       Date:  2006-09-21       Impact factor: 5.157

Review 3.  Reduction-sensitive polymers and bioconjugates for biomedical applications.

Authors:  Fenghua Meng; Wim E Hennink; Zhiyuan Zhong
Journal:  Biomaterials       Date:  2009-02-05       Impact factor: 12.479

4.  Biomarker Development for the Clinical Activity of the mTOR Inhibitor Everolimus (RAD001): Processes, Limitations, and Further Proposals.

Authors:  Terence O'Reilly; Paul Mj McSheehy
Journal:  Transl Oncol       Date:  2010-04       Impact factor: 4.243

5.  Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

Authors:  Vladimir J N Bykov; Natalia Issaeva; Nicole Zache; Alexandre Shilov; Monica Hultcrantz; Jan Bergman; Galina Selivanova; Klas G Wiman
Journal:  J Biol Chem       Date:  2017-12-01       Impact factor: 5.157

6.  Systemic delivery of factor IX messenger RNA for protein replacement therapy.

Authors:  Suvasini Ramaswamy; Nina Tonnu; Kiyoshi Tachikawa; Pattraranee Limphong; Jerel B Vega; Priya P Karmali; Pad Chivukula; Inder M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-15       Impact factor: 11.205

Review 7.  Chloroquine in cancer therapy: a double-edged sword of autophagy.

Authors:  Tomonori Kimura; Yoshitsugu Takabatake; Atsushi Takahashi; Yoshitaka Isaka
Journal:  Cancer Res       Date:  2013-01-01       Impact factor: 12.701

8.  An Orthogonal Array Optimization of Lipid-like Nanoparticles for mRNA Delivery in Vivo.

Authors:  Bin Li; Xiao Luo; Binbin Deng; Junfeng Wang; David W McComb; Yimin Shi; Karin M L Gaensler; Xu Tan; Amy L Dunn; Bryce A Kerlin; Yizhou Dong
Journal:  Nano Lett       Date:  2015-11-06       Impact factor: 11.189

9.  Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.

Authors:  Michael Andreeff; Kevin R Kelly; Karen Yee; Sarit Assouline; Roger Strair; Leslie Popplewell; David Bowen; Giovanni Martinelli; Mark W Drummond; Paresh Vyas; Mark Kirschbaum; Swaminathan Padmanabhan Iyer; Vivian Ruvolo; Graciela M Nogueras González; Xuelin Huang; Gong Chen; Bradford Graves; Steven Blotner; Peter Bridge; Lori Jukofsky; Steve Middleton; Monica Reckner; Ruediger Rueger; Jianguo Zhi; Gwen Nichols; Kensuke Kojima
Journal:  Clin Cancer Res       Date:  2015-10-12       Impact factor: 12.531

10.  Pharmaceutical screen identifies novel target processes for activation of autophagy with a broad translational potential.

Authors:  Santosh Chauhan; Zahra Ahmed; Steven B Bradfute; John Arko-Mensah; Michael A Mandell; Seong Won Choi; Tomonori Kimura; Fabien Blanchet; Anna Waller; Michal H Mudd; Shanya Jiang; Larry Sklar; Graham S Timmins; Nicole Maphis; Kiran Bhaskar; Vincent Piguet; Vojo Deretic
Journal:  Nat Commun       Date:  2015-10-27       Impact factor: 14.919

View more
  43 in total

1.  siRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice.

Authors:  Wei Tao; Arif Yurdagul; Na Kong; Wenliang Li; Xiaobo Wang; Amanda C Doran; Chan Feng; Junqing Wang; Mohammad Ariful Islam; Omid C Farokhzad; Ira Tabas; Jinjun Shi
Journal:  Sci Transl Med       Date:  2020-07-22       Impact factor: 17.956

2.  Molecular determinants of response to PI3K/akt/mTOR and KRAS pathways inhibitors in NSCLC cell lines.

Authors:  Alice Iezzi; Elisa Caiola; Marika Colombo; Mirko Marabese; Massimo Broggini
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

Review 3.  The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation.

Authors:  Hui Cao; Xiaosong Chen; Zhijun Wang; Lei Wang; Qiang Xia; Wei Zhang
Journal:  Cell Death Discov       Date:  2020-06-19

4.  Formulation and Delivery Technologies for mRNA Vaccines.

Authors:  Chunxi Zeng; Chengxiang Zhang; Patrick G Walker; Yizhou Dong
Journal:  Curr Top Microbiol Immunol       Date:  2020-06-02       Impact factor: 4.291

Review 5.  Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages.

Authors:  Xiangang Huang; Chuang Liu; Na Kong; Yufen Xiao; Arif Yurdagul; Ira Tabas; Wei Tao
Journal:  Nat Protoc       Date:  2022-02-04       Impact factor: 13.491

6.  Synthesis of RNA-based gene regulatory devices for redirecting cellular signaling events mediated by p53.

Authors:  Xinbo Huang; Mingxia Wang; Yuchen Liu; Yaoting Gui
Journal:  Theranostics       Date:  2021-03-04       Impact factor: 11.556

7.  mRNA Delivery of a Bispecific Single-Domain Antibody to Polarize Tumor-Associated Macrophages and Synergize Immunotherapy against Liver Malignancies.

Authors:  Ying Wang; Karthik Tiruthani; Sirui Li; Mengying Hu; Guojie Zhong; Yu Tang; Sourav Roy; Lillian Zhang; Jun Tan; Chengheng Liao; Rihe Liu
Journal:  Adv Mater       Date:  2021-05-04       Impact factor: 32.086

8.  Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models.

Authors:  Yao-Xin Lin; Yi Wang; Jianxun Ding; Aiping Jiang; Jie Wang; Mian Yu; Sara Blake; Shuaishuai Liu; Charles J Bieberich; Omid C Farokhzad; Lin Mei; Hao Wang; Jinjun Shi
Journal:  Sci Transl Med       Date:  2021-06-23       Impact factor: 17.956

Review 9.  Recent Advances in Stimulus-Responsive Nanocarriers for Gene Therapy.

Authors:  Cheng Yu; Long Li; Pei Hu; Yan Yang; Wei Wei; Xin Deng; Lu Wang; Franklin R Tay; Jingzhi Ma
Journal:  Adv Sci (Weinh)       Date:  2021-05-16       Impact factor: 16.806

Review 10.  Harnessing lipid nanoparticles for efficient CRISPR delivery.

Authors:  Jingyue Yan; Diana D Kang; Yizhou Dong
Journal:  Biomater Sci       Date:  2021-09-14       Impact factor: 7.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.